Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bausch + Lomb Corporation Common Shares (NY:BLCO)

14.46 -0.21 (-1.43%)
Streaming Delayed Price Updated: 11:03 AM EDT, Oct 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bausch + Lomb Corporation Common Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Bausch + Lomb Will Release Third-Quarter 2025 Financial Results on Oct. 29 and Hold Investor Day on Nov. 13
From Bausch + Lomb Corporation
Via Business Wire
1 Small-Cap Stock to Keep an Eye On and 2 That Underwhelm
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a... 
Via StockStory
Bausch + Lomb, Enovis, and Haemonetics Shares Plummet, What You Need To Know
A number of stocks fell in the afternoon session after the U.S. Commerce Department initiated a national security investigation into medical equipment and devices, raising concerns about potential... 
Via StockStory
Topics Economy Government World Trade
Earnings Scheduled For July 30, 2025
 
Via Benzinga
Examining the Future: Bausch & Lomb's Earnings Outlook
 
Via Benzinga
Bausch + Lomb Announces Publication of enVista Envy™ Full Range of Vision Intraocular Lens Pivotal U.S. Clinical Trial
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Announces Publication of Data From a Prospective Study Evaluating the Efficacy of XIIDRA® in Alleviating Discomfort in Symptomatic Contact Lens Wearers
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb (BLCO) Stock Trades Up, Here Is Why
Shares of eyecare company Bausch + Lomb (NYSE:BLCO) jumped 2.9% in the afternoon session after the company announced the U.S. launch of its ASANA gas permeable (GP) lenses. This new product line offers... 
Via StockStory
Topics Economy Initial Public Offering Stocks
Bausch + Lomb Launches ASANA™ Gas Permeable Lenses in the United States
From Bausch + Lomb Corporation
Via Business Wire
3 Healthcare Stocks Walking a Fine Line
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destockings have persisted in the wake of... 
Via StockStory
Topics Stocks
Bausch + Lomb (BLCO) Stock Is Up, What You Need To Know
Shares of eyecare company Bausch + Lomb (NYSE:BLCO) jumped 3.1% in the afternoon session after comments from Federal Reserve Chair Jerome Powell raised investor hopes for future interest rate cuts. The... 
Via StockStory
Topics Economy Initial Public Offering Stocks
Purple, Bausch + Lomb, Etsy, Intel, and Camping World Shares Are Falling, What You Need To Know
A number of stocks fell in the afternoon session after markets continued to decline, as investors grew cautious ahead of a key speech by Federal Reserve Chair Jerome Powell. The move came as U.S.... 
Via StockStory
Topics Economy Stocks
Medical Devices & Supplies - Specialty Stocks Q2 Highlights: Bausch + Lomb (NYSE:BLCO)
As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the medical devices & supplies - specialty industry, including Bausch + Lomb... 
Via StockStory
Bausch + Lomb Announces Board Changes
From Bausch + Lomb Corporation
Via Business Wire
1 Safe-and-Steady Stock with Competitive Advantages and 2 That Underwhelm
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets. 
Via StockStory
Bausch + Lomb to Participate in Upcoming Investor Conferences
From Bausch + Lomb Corporation
Via Business Wire
Sotera Health Company, Incyte, Exact Sciences, Bausch + Lomb, and Addus HomeCare Shares Skyrocket, What You Need To Know
A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending interest rate cut by the Federal Reserve. Following a favorable Consumer... 
Via StockStory
Topics Economy Lawsuit
BLCO Q2 Deep Dive: Product Launches Offset Margin Pressures, Management Highlights Pipeline Investments
Eyecare company Bausch + Lomb (NYSE:BLCO) announced better-than-expected revenue in Q2 CY2025, with sales up 5.1% year on year to $1.28 billion. The company’s full-year revenue guidance of $5.1 billion... 
Via StockStory
1 Stock Under $50 to Target This Week and 2 We Ignore
Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some... 
Via StockStory
3 Small-Cap Stocks with Warning Signs
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a... 
Via StockStory
Bausch Lomb (BLCO) Q2 Revenue Rises 5%
Via The Motley Fool
Why Bausch + Lomb (BLCO) Stock Is Down Today
Shares of eyecare company Bausch + Lomb (NYSE:BLCO) fell 3.1% in the morning session after the company reported mixed second-quarter 2025 financial results where a decline in profitability overshadowed... 
Via StockStory
Topics Artificial Intelligence Initial Public Offering
Bausch + Lomb’s (NYSE:BLCO) Q2 Sales Top Estimates, Full-Year Outlook Slightly Exceeds Expectations
Eyecare company Bausch + Lomb (NYSE:BLCO) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 5.1% year on year to $1.28 billion. The company’s full-year revenue guidance... 
Via StockStory
Bausch + Lomb Announces Second-Quarter 2025 Results
From Bausch + Lomb Corporation
Via Business Wire
Bausch Health Adds Late-Stage Ready Alcohol Liver Disease Drug Candidate In $63 Million DURECT Buyout
Bausch Health will acquire DURECT and larsucosterol, aiming for FDA approval of a first treatment for alcoholic hepatitis via Phase 3 trials. 
Via Benzinga
Bausch + Lomb Announces Publication of Phase 3 Data on LUMIFY® Preservative Free Redness Reliever Eye Drops
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb (BLCO) Q2 Earnings Report Preview: What To Look For
Eyecare company Bausch + Lomb (NYSE:BLCO) will be reporting earnings this Wednesday before market hours. Here’s what investors should know. 
Via StockStory
Topics Artificial Intelligence
Artificial Intelligence Influence in Ophthalmology Industry Projected to Create a Billion Dollar Revenue Opportunity
EQNX::TICKER_START (OTCQB:AVAI),(NYSE:ALC),(NYSE:BLCO),(NYSE:JNJ),(NASDAQ:TEM) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
Medical Devices & Supplies - Specialty Stocks Q1 In Review: Bausch + Lomb (NYSE:BLCO) Vs Peers
Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Bausch + Lomb (NYSE:BLCO) and its peers. 
Via StockStory
Deal Dispatch: Del Taco Tanks, Tylenol Maker Aches For Change, Joyebells Burns The Pie
This week's M&A news includes strategic pivots and stumbles galore, with updates from WK Kellogg, Matador Restaurant and Windsurf. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.